Societies, associations and institutes develop clinical guidelines for the treatment and management of Psoriasis at local, national, and international levels. The selections of guidelines below will aid healthcare professionals in the diagnosis, treatment, and management of their patients.
Guidelines for the management of psoriasis with topical therapies were developed by the American Academy of Dermatology (AAD) in 2009 (Menter et al., 2009). These guidelines highlight that the majority of patients with psoriasis have limited disease (<5% body surface area [BSA] involvement) and can be safely and effectively treated with topical agents tailored to meet individual patients’ needs (Menter et al., 2009). Updates to these guidelines are expected to be published by the AAD in collaboration with the National Psoriasis Foundation (NPF) in the second quarter of 2020. All AAD guidelines can be accessed below.
Joint AAD-NPF guidelines on biologic and non-biologic treatment
All AAD guidelines can be accessed below. Joint AAD-NPF guidelines highlight that anti-TNF biosimilars approved by the FDA should be considered as interchangeable with the reference brand and that biologics may lose efficacy in patients who initially respond well to treatment (Menter et al., 2019).
Joint AAD-NPF guidelines of care for the management of psoriasis with non-biologics are expected in the first quarter of 2020.
Psoriasis and comorbidity guidelines
To help ensure physicians include prompt diagnosis of concomitant disease and prevent and treat any comorbidity, the EADV developed a precise, easy-to-use tool for systematising the diagnosis of comorbidity in patients with psoriasis and facilitate decision making regarding referral and treatment of patients diagnosed with an associated disease.
AAD-NPF guidelines were also published in 2019 covering the management and treatment of comorbidities that occur in patients with psoriasis. The guidelines provide an overview of the most common comorbidities and recommendations for screening and referral of these conditions (Elmets et al., 2019). The importance of patient and physician education surrounding these comorbidities was highlighted by Randy Beranek, president and CEO of the NPF (AAD, 2019):
“it is critical for both patients and doctors to understand the complexity of psoriasis. It is not just a skin disease; it is a serious condition that can affect all aspects of a patient’s health”.
Professor Andrew Blauvelt discussed the comorbidities that are a challenge to psoriasis treatment.
This downloadable PDF guideline from Scottish Intercollegiate Guidelines Network (SIGN) provides recommendations based on current evidence for best practice in the diagnosis and management of psoriasis and PsA in adults.
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–1113.